

THE INTERNATIONAL LIVER CONGRESS™

Savour science
together again

22-26
JUNE
2022
LONDON



www.easl.eu/ilc2022

#ILC2022

 **EASL™**
The Home of Hepatology

Wed, 22 June 2022 14:30 - 16:00 90 minutes	<u>Postgraduate course - The future of clinical hepatology: Liver support and regeneration</u>	Organisers: <u>Andres Cardenas</u> <u>Norah Terrault</u> Chairs: <u>Anil Dhawan</u> <u>Didier Samuel</u>
14:30 - 14:40	Case presentation: Artificial support in patient with ACLF awaiting Liver transplantation	<u>Audrey Coilly, France</u>
14:40 - 14:55	Clinical applications of Liver Support	<u>Faouzi Saliba, France</u>
14:55 - 15:10	Hepatocyte Transplantation in ALF in Children	<u>Anil Dhawan, United Kingdom</u>
15:10 - 15:25	Progress and limits in the use of liver cells in clinical practice	<u>Fotios Sampaziotis, United Kingdom</u>
15:25 - 15:40	Safer liver surgery and transplantation through repair and enhanced regeneration	<u>Pierre Clavien, Switzerland</u>
15:40 - 16:00	Discussion and Q&A	





Fri, 24 June 2022 10:00 - 11:30 90 minutes	<u>Abstract session: Viral hepatitis elimination</u>	Chairs: <u>Ziv Ben Ari</u> <u>Sharon Hutchinson</u>
10:00 - 10:15	OS049 Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia	<u>Xiaohui Sem, Malaysia</u>
10:15 - 10:30	OS050 The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road	<u>Devin Razavi-Shearer, United States</u>
10:30 - 10:45	OS051 The HCV care cascade for children and young people in British Columbia, Canada: a large, linked administrative population-based cohort study	<u>Dahn Jeong, Canada</u>
10:45 - 11:00	OS052 Clinical impact and cost-effectiveness of hepatitis C testing in an emergency department in Barcelona, Spain	<u>Jordi Llaneras, Spain</u>
11:00 - 11:15	OS053 High Intensity Test and Treat (HITT): an overview of the initiative as part of the hepatitis C elimination programme in England	<u>Beatrice Emmanouil, United Kingdom</u>
11:15 - 11:30	OS054 Hepatitis C elimination in diabetic population from a shared care cascade cohort- under Changhua-Integrated Program to Stop hepatitis C infection (CHIPS-C)	<u>Tsung-Hui Hu, Taiwan</u>





<p>Fri, 24 June 2022 16:00 - 17:30 90 minutes</p>	<p><u>EASL-CDC-WHO symposium: Innovations in hepatitis elimination and launch of WHO HCV guidelines on simplified service delivery and diagnostics</u></p>	<p>Chairs: <u>Paige A Armstrong</u> <u>Maria Buti</u> <u>Philippa Easterbrook</u></p>
<p>16:00 - 16:05</p>	<p>Welcome remarks and introduction of speakers</p>	
<p>16:05 - 16:20</p>	<p>New WHO guidance on HCV simplified service delivery and diagnostic innovations and treatment of children/adolescents</p>	<p><u>Philippa Easterbrook, Switzerland</u></p>
<p>16:20 - 16:32</p>	<p>Cambodia - decentralization to primary care, task-shifting to nurses, and use of PoC viral load</p>	<p><u>Mickael Le Paih, Cambodia</u></p>
<p>16:32 - 16:44</p>	<p>Towards elimination: A clinical and public health approach to control of hepatitis C and B infection in England</p>	<p><u>Graham Foster, United Kingdom</u></p>
<p>16:44 - 16:56</p>	<p>Egypt – Case-finding strategies to reach the children and adolescents</p>	<p><u>Manal Hamdy El-Sayed, Egypt</u></p>
<p>16:56 - 17:08</p>	<p>Uganda – Integrated service delivery of HBV and HIV care</p>	<p><u>Ponsiano Ocama, Uganda</u></p>
<p>17:08 - 17:30</p>	<p>Panel discussion and Q&A</p>	





<p>Sat, 25 June 2022 16:00 - 17:00 60 minutes</p>	<p><u>Symposium: Tumour heterogeneity in liver cancer implications for diagnosis and treatment</u></p>	<p>Chairs: <u>Thomas Bird</u> <u>Jessica Zucman-Rossi</u></p>
<p>16:00 - 16:03</p>	<p>Introduction</p>	<p>Panel: <u>Thomas Bird (Chair)</u>, <u>Jessica Zucman-Rossi (Chair)</u></p>
<p>16:03 - 16:15</p>	<p>Molecular heterogeneity of paediatric liver cancers</p>	<p><u>Theo Hirsch, France</u></p>
<p>16:15 - 16:27</p>	<p>Understanding liver tumour heterogeneity at diagnosis</p>	<p><u>Valérie Paradis, France</u></p>
<p>16:27 - 16:39</p>	<p>Intratumoural immune heterogeneity as a hallmark of tumour evolution in HCC</p>	<p><u>Valerie Chew, Singapore</u></p>
<p>16:39 - 17:00</p>	<p>Discussion and Q&A</p>	





Selected poster presentation:

Posters are available as ePoster Wed-Sun, but presenter will be next to their poster on the day indicated below:

Thu, 23 June 2022	A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis	Lukas Van Melkebeke, Belgium
Thu, 23 June 2022	Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study	Jaejun Lee, Korea, Rep. of South
Thu, 23 June 2022	The impact of vaccination on the global and regional pediatric prevalence of hepatitis B from 1985-2022	Devin Shearer, United States
Thu, 23 June 2022	Global survey of healthcare workers' attitudes to treatment of chronic hepatitis C infection in children and adolescents	Farihah Malik, United Kingdom
Thu, 23 June 2022	The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection	Ivana Carey, United Kingdom





Selected poster presentation:

Posters are available as ePoster Wed-Sun, but presenter will be next to their poster on the day indicated below:

Fri, 24 June 2022	Plasma metabolomics and machine learning characterizes metabolite signature capable of segregating patients with poor outcome in pediatric cirrhosis	Lili Niu, Denmark
Fri, 24 June 2022	Senolytic therapies have a place in pediatric biliary cirrhosis	Giulia Jannone, Belgium
Fri, 24 June 2022	MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis	Piotr Pawliszak, Poland
Fri, 24 June 2022	Plasma proteomics identifies hepatic steatosis and sex differences in 2,147 children and adolescents	Lili Niu, Denmark
Fri, 24 June 2022	Treating children with HCV close to home through a virtual national multidisciplinary network	Deirdre Kelly, United Kingdom





Selected poster presentation:

Posters are available as ePoster Wed-Sun, but presenter will be next to their poster on the day indicated below:

Fri, 24 June 2022	High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations	Giuseppe Indolfi, Italy
Fri, 24 June 2022	Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis	Kushala Abeysekera, United Kingdom
Fri, 24 June 2022	The relationship between foetal head circumference growth trajectories and nonalcoholic fatty liver disease in adolescents	Jeffrey Lee, Australia
Fri, 24 June 2022	Preserved MAIT cell proinflammatory function in children with autoimmune liver disease	Suzan Warner, United Kingdom
Fri, 24 June 2022	An adult-based genetic risk score for hepatic fat associates with liver and lipid traits in Danish children and adolescents	Yun Huang, Denmark



22-26
JUNE
2022
LONDON

Selected poster presentation:

Posters are available as ePoster Wed-Sun, but presenter will be next to their poster on the day indicated below:

Sat, 25 June 2022	Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B	Kathleen Schwarz, United States
--------------------------	--	------------------------------------

* Please note: Programme subject to change; version as of May 2022; all stated times correspond to BST Time.

